Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:12
  • preuzimanja u poslednjih 30 dana:5

Sadržaj

članak: 7 od 28  
Back povratak na rezultate
2017, vol. 56, br. 4, str. 50-60
Hronični hepatitis B
aKliničko-bolnički centar Priština, Gračanica, Laplje selo
bUniverzitet u Prištini sa privremenim sedištem u Kosovskoj Mitrovici, Medicinski fakultet
cUniverzitet u Nišu, Medicinski fakultet

e-adresavanja.nickovic@gmail.com
Sažetak
Virus hepatitisa B je primarno hepatotropni virus koji je izazivač kako akutnog tako i hroničnog hepatitisa B. Primarni hronični hepatitis B je najčešće samoograničavajuća bolest sa kompletnim izlečenjem za 2-3 meseca od početka bolesti. Smatra se da je 2/3 svetske populacije tokom života bilo u kontaktu sa hepatitis B virusom. Zahvaljujući uvođenju obavezne imunizacije protiv hepatitisa B, učestalost hroničnog hepatitisa B je prema podacima Svetske zdravstvene organizacije u opadanju. Međutim, kod oko 400 miliona ljudi svetske populacije razviće se hronični hepatitis B. Činjenica je da godišnje širom sveta umire više od jednog miliona ljudi od hroničnog hepatitisa, ciroze jetre ili hepatocelularnog karcinoma (HCC). To znači da je hronični hepatitis B globalni zdravstveni problem. Pravovremena dijagnoza i adekvatna terapija značajno usporavaju tok i progresiju hroničnog hepatitisa B.
Reference
Aspinall, E. J., Hawkins, G., Fraser, A., Hutchinson, S. J., Goldberg, D. (2011) Hepatitis B prevention, diagnosis, treatment and care: a review. Occupational Medicine, 61(8): 531-540
Bonino, F., Piratvisuth, T., Brunetto, M.R., Liaw, Y. (2010) Diagnostic markers of chronic hepatitis B infection and disease. Antiviral Therapy, 15(Suppl 3): 35-44
Borgia, G., Gentile, I. (2014) Vertical transmission of hepatitis B virus: challenges and solutions. International Journal of Women's Health, str. 605
Brunetto, M.R., Oliveri, F., Colombatto, P., Moriconi, F., Ciccorossi, P., Coco, B., Romagnoli, V., Cherubini, B., Moscato, G., Maina, A.M., Cavallone, D., Bonino, F. (2010) Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers. Gastroenterology, 139(2): 483-490
Caligiuri, P. (2016) Overview of hepatitis B virus mutations and their implications in the management of infection. World Journal of Gastroenterology, 22(1): 145
Chen, J., Yang, Hwai-I., Iloeje, U.H., You, S., Lu, S., Wang, L., Su, J., Sun, C., Liaw, Y., Chen, C. (2010) Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related Death. Gastroenterology, 138(5): 1747-1754.e1
Chisari, F.V., Isogawa, M., Wieland. S.F. (2010) Pathogenesis of hepatitis B virus infection. Pathologie Biologie, 58(4): 258-266
Coppola, N. (2015) Clinical significance of hepatitis B surface antigen mutants. World Journal of Hepatology, 7(27): 2729
Croagh, C.M. (2015) Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance. World Journal of Hepatology, 7(3): 289
Datta, S., Chatterjee, S., Veer, V., Chakravarty, R. (2012) Molecular Biology of the Hepatitis B Virus for Clinicians. Journal of Clinical and Experimental Hepatology, 2(4): 353-365
Delić, D., Nikolić, P., Božić, M. (1998) Virusni hepatitisi. Beograd: Zavod za udžbenike i nastavna sredstva
Fiel, M. I. (2010) Pathology of Chronic Hepatitis B and Chronic Hepatitis C. Clinics in Liver Disease, 14(4): 555-575
Fiel, M.I. (2017) Histologic scoring systems for chronic liver disease. https://www.uptodate.com/contents/histologicscoring-systems-for-chronic-liver-disease, 2017 July, cited 2017 Sep 5
Gao, S. (2015) Clinical relevance of hepatitis B virus variants. World Journal of Hepatology, 7(8): 1086
Gerlich, W.H. (2015) Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Medical Microbiology and Immunology, 204(1): 39-55
Hagiwara, S., Kudo, M., Osaki, Y., Matsuo, H., Inuzuka, T., Matsumoto, A., Tanaka, E., Sakurai, T., Ueshima, K., Inoue, T., Yada, N., Nishida, N. (2013) Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. Journal of Medical Virology, 85(6): 987-995
Haviari, S., Bénet, T., Saadatian-Elahi, M., André, P., Loulergue, P., Vanhems, P. (2015) Vaccination of healthcare workers: A review. Human Vaccines & Immunotherapeutics, 11(11): 2522-2537
Isogawa, M., Tanaka, Y. (2014) Immunobiology of hepatitis B virus infection. Hepatology Research, 45(2): 179-189
Janssen, H.L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U.S., Cakaloglu, Y., Simon, C., So, T.M., Gerken, G., de Man, R.A., Niesters, H.G., Zondervan, P., Hansen, B., Schalm, S.W. (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet, 365(9454): 123-129
Kao, J. (2011) Molecular Epidemiology of Hepatitis B Virus. Korean Journal of Internal Medicine, 26(3): 255
Komatsu, H. (2014) Hepatitis B virus: Where do we stand and what is the next step for eradication. World J Gastroenterol, 20(27): 8998-9016
LeFevre, M.L. (2014) Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, 161(1): 58
Liang, T. J. (2009) Hepatitis B: The virus and disease. Hepatology, 49(S5): S13-S21
Liang, Y., Jiang, J., Su, M., Liu, Z., Guo, W., Huang, X., Xie, R., Ge, S., Hu, J., Jiang, Z., Zhu, M., Wong, V. W.-S., Chan, H. L.-Y. (2011) Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Alimentary Pharmacology & Therapeutics, 34(3): 344-352
Liaw, Y. (2011) Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review. Hepatology, 53(6): 2121-2129
Liu, Y., Zhang, L., Zhou, J., Pan, J., Hu, W., Zhou, Y. (2016) Clinical and Virological Characteristics of Chronic Hepatitis B Patients with Coexistence of HBsAg and Anti-HBs. PLoS One, 11(1): e0146980
Maiwall, R., Kumar, M. (2016) Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. Journal of Clinical and Translational Hepatology, 4(1): 54-65
Marcellin, P., Heathcote, E. J., Buti, M., Gane, E., de Man, R.A., Krastev, Z., Germanidis, G., Lee, S.S., Flisiak, R., Kaita, K., Manns, M., Kotzev, I., Tchernev, K., Buggisch, P., Weilert, F. (2008) Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B. New England Journal of Medicine, 359(23): 2442-2455
McMahon, B.J. (2016) Combination of Pegylated Interferon and Tenofovir for Hepatitis B Treatment: Screening and Counseling of Patients are Warranted. Gastroenterology, 150(1): 32-34
Navabakhsh, B., Mehrabi, N., Estakhri, A., Mohamadnejad, M., Poustchi, H. (2011) Hepatitis B virus infection during pregnancy: transmission and prevention. Middle East J Dig Dis, 3(2): 92-102
Pande, C., Kumar, A., Patra, S., Trivedi, S.S., Dutta, A.K., Sarin, S.K. (2008) High maternal hepatitis DNA levels but not HBeAg positivity predicts perinatal transmission of hepatitis B to the newborn. DDW, A252
Peng, C. (2013) Nucleos(t)ide Analogues Therapy for Chronic Hepatitis B in Taiwan: Short-Term Versus Long-Term. Current Hepatitis Reports, 12(3): 181-187
Perrillo, R. (2009) Benefits and risks of interferon therapy for hepatitis B. Hepatology, 49(S5): S103-S111
Reaiche, G.Y., le Mire, M.F., Mason, W.S., Jilbert, A.R. (2010) The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis. Virology, 406(2): 286-292
Romanò, L., Paladini, S., Galli, C., Raimondo, G., Pollicino, T., Zanetti, A.R. (2015) Hepatitis B vaccination. Human Vaccines & Immunotherapeutics, 11(1): 53-57
Schillie, S., Murphy, T.V., Sawyer, M., Ly, K., Hughes, E., Jiles, R., i dr. (2013) CDC guidance for evaluating healthcare personnel for hepatitis B virus protection and for administering postexposure management. MMWR-Morbid Mortal W, 62(RR10), 1-19
Schmidt, W.N., Nelson, D.R., Pawlotsky, J., Sherman, K.E., Thomas, D.L., Chung, R.T. (2014) Direct-Acting Antiviral Agents and the Path to Interferon Independence. Clinical Gastroenterology and Hepatology, 12(5): 728-737
Schuch, A., Hoh, A., Thimme, R. (2014) The Role of Natural Killer Cells and CD8+ T Cells in Hepatitis B Virus Infection. Frontiers in Immunology, 5:258
Shuai, Z., Leung, M.W., He, X., Zhang, W., Yang, G., Leung, P.S., Eric, G.M. (2016) Adaptive immunity in the liver. Cellular & Molecular Immunology, 13(3): 354-368
Su, T., Hsu, C., Chen, C., Liu, C., Huang, Y., Tseng, T., Liu, C., Chen, P., Lai, M., Chen, D., Kao, J. (2010) Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antiviral Therapy, 15(8): 1133-1139
Terrier, B., Cacoub, P. (2011) Virus de l’hépatite B, manifestations extrahépatiques immunologiques et risque de réactivation virale. La Revue de Médecine Interne, 32(10): 622-627
Thompson, A.J.V., Nguyen, T., Iser, D., Ayres, A., Jackson, K., Littlejohn, M., Slavin, J., Bowden, S., Gane, E.J., Abbott, W., Lau, G.K.K., Lewin, S.R., Visvanathan, K., Desmond, P.V., Locarnini, S. (2010) Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology, 51(6): 1933-1944
Tseng, T., Liu, C., Chen, C., Wang, C., Su, T., Kuo, S.F., Chen, P., Chen, D., Kao, J. (2011) Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters. Journal of Infectious Diseases, 205(1): 54-63
Wong, G.L. (2014) Prediction of fibrosis progression in chronic viral hepatitis. Clinical and Molecular Hepatology, 20(3): 228
Wong, S.Y., Hann, H.W. (2013) Hepatitis B-related hepatocellular carcinoma. OA Hepatology, 1(1), 7
Yang, H., Kao, J. (2014) Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerging Microbes & Infections, 3(9): e64-e64
Yim, H.J., Byun, K.S., Chang, Y.J., Suh, Y.S., Yeon, J.E., Lee, C.H., Kwon, J.A., Yoo, W., Kim, S., Hong, S.P. (2007) Levels of Hepatitis B Virus (HBV) Replication During the Nonreplicative Phase: HBV Quantification by Real-Time PCR in Korea. Digestive Diseases and Sciences, 52(9): 2403-2409
 

O članku

jezik rada: engleski
vrsta rada: pregledni članak
DOI: 10.5633/amm.2017.0408
objavljen u SCIndeksu: 15.03.2018.
Creative Commons License 4.0